BioWorld Asia

Dec. 17, 2003

Acambis Files 'First-Ever' BLA: Arilvax Vaccine In Yellow Fever

Acambis plc filed a biologics license application seeking approval of Arilvax as a vaccine to prevent yellow fever. (BioWorld International) Read More

Arpida Moving Iclaprim Into Phase III Trial, Seeking EUR25M

Trial To Test Recombinant Poxvirus Vaccine In Malaria

Genmab Stops HuMax-CD4 Development In Psoriasis

Ingenium Plans Growth After Third Round Brings In EUR13.8M

Benitec Settles ddRNAi Dispute, Raises A$10.9M To Fund Growth

Faust Pharmaceuticals Acquires Euroclide, Seeks EUR12M Funding

Innate Pharma, Novo Nordisk In Cancer Immunotherapy Deal

Novacea Licenses Cancer Drug From KuDOS Pharmaceuticals

London Cluster Growing But Lab Space Shortage Impedes

EU Moving Closer To New Rules On Pharmaceuticals, Tissues, Cells

Industry Representatives Meet In Israel To Discuss Bioengineering

Fulcrum To Help Addex Build Internal Clinical Development

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 31, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...